A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Фаза 2
Завершено
NCT06176963
| Заболевание | Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Samsung Bioepis Co., Ltd. |
|---|
| Статус | Завершено |
|---|
| Участники | 34 участн. |
|---|
| Вмешательство | SB11 PFS |
|---|
| Дата начала | 21.11.2023 |
|---|
| Дата завершения | 30.11.2023 |
|---|
| Публикация результатов | 30.12.2024 |
|---|
Кратко
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to subjects with nAMD or Macular Oedema Secondary to RVO.
Percentage of Successful Task Completions
Day 1 · Percentage of successful task completion
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
| SB11 PFS | 100 Percentage of successful task completion |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.